[1]于　艳,何　萌,杨　晶,等.多发性骨髓瘤患者血清miR-1246和miR-4449的表达及临床意义[J].现代检验医学杂志,2022,37(02):85-87.[doi:10.3969/j.issn.1671-7414.2022.02.018]
　YU Yan,HE Meng,YANG Jing,et al.Expression and Clinical Significance of Serum miR-1246 and miR-4449 in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2022,37(02):85-87.[doi:10.3969/j.issn.1671-7414.2022.02.018]
点击复制

多发性骨髓瘤患者血清miR-1246和miR-4449的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
85-87
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Expression and Clinical Significance of Serum miR-1246 and miR-4449 in Patients with Multiple Myeloma
文章编号:
1671-7414（2022）02-085-04
作者:
于　艳; 何　萌; 杨　晶; 王莉莉
( 涿州市医院检验科，河北涿州 　072750)
Author(s):
YU Yan;  HE Meng;  YANG Jing;  WANG Li-li
（Department of Clinical Laboratory, Zhuozhou City Hospital，Hebei Zhuozhou 072750, China）
关键词:
多发性骨髓瘤; 微小核糖核酸-1246; 微小核糖核酸-4449
分类号:
R733.3；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.018
文献标志码:
A
摘要:
目的　探讨多发性骨髓瘤（multiple myeloma, MM）患者血清miR-1246 及miR-4449 的表达及其临床意义。方法　选取2017 年1 月~2020 年10 月涿州市医院收治的85 例MM 患者，依据国际分期系统分为I 期（n=17），II 期（n=27）和III 期（n=41），按照MM 的诊疗情况分为初诊组（n=68）和复发组（n=17）。另选取同期50 例正常者作为对照组。检测各组血清miR-1246，miR-4449 及β2- 微球蛋白（β2-MG）水平。应用受试者工作特征（ROC）曲线分析血清miR-1246，miR-4449 及β2-MG 水平诊断MM 的价值。结果　MM 组血清miR-1246（1.95±0.86），miR-4449（2.50±1.08）及β2-MG（6.30±2.42 mg/L）水平均明显高于对照组（0.42±0.07，0.73±0.16，1.85±0.64mg/L），差异有统计学意义（t=13.348, 14.365, 12.910, 均P<0.001）。MM 患者III 期血清miR-1246（3.05±1.37），miR-4449（3.96±1.87）及β2-MG（9.37±4.10 mg/L）水平均明显高于I 期（0.86±0.25，1.07±0.34，3.52±1.05mg/L）和II 期（1.84±0.81，2.28±1.05，5.40±1.61mg/L），差异有统计学意义（均P<0.001），且II 期血清miR-1246，miR-4449及β2-MG水平均明显高于I 期，差异有统计学意义（P<0.001）。复发组血清miR-1246（2.61±1.13），miR-4449（3.18±1.64）及β2-MG（8.04±3.27 mg/L）水平均明显高于初诊组(1.55±0.62, 1.92±0.95, 4.96±1.85mg/L)，差异均有统计学意义（t =10.217, 12.116, 8.530，均P<0.001）。ROC 曲线分析显示，miR-1246，miR-4449 及β2-MG 三项联合诊断MM 的曲线下面积（0.950，95%CI：0.887~0.995）最大，其灵敏度和特异度为98.2% 和85.0%。结论　MM 患者血清miR-1246及miR-4449 表达水平明显升高，且随着MM病情分期进展呈升高趋势，联合β2-MG检测有助于提高MM诊断的灵敏度。
Abstract:
Objective　To investigate the expression and clinical significance of serum miR-1246 and miR-4449 in patients with multiple myeloma (MM). Methods　The 85 patients with MM admitted to Zhuozhou Hospital from January 2017 to July 2020 were divided into stage I (n=17), stage II (n=27) and stage III (n=41) according to the international staging system. According to the diagnosis and treatment of MM, they were divided into initial diagnosis group (n=68) and recurrence group (n=17). Another 50 normal persons in the same period were selected as the control group. The levels of serum miR-1246，miR-4449 and β2-MG were measured in each group. The diagnostic value of serum miR-1246，miR-4449 and β2-MG in MM were analyzed by ROC curve. Results　The levels of serum miR-1246（1.95±0.86）, miR-4449（2.50±1.08） and β2-MG（6.30±2.42 mg/L） in MM group were significantly higher than those in control group(0.42±0.07, 0.73±0.16, 1.85±0.64mg/L)，the differences were statistically significant（t=13.348, 14.365, 12.910, all P<0.001）.The levels of serum miR-1246（3.05±1.37）, miR-4449 （3.96±1.87） and β2-MG（9.37±4.10 mg/L）in MM patients at stage III were significantly higher than those at stage I(0.86±0.25, 1.07±0.34, 3.52±1.05mg/L) and II (1.84±0.81, 2.28±1.05, 5.40±1.61mg/L), the diffrences were statistically significant(P<0.001). The levels of serum miR-1246, miR-4449 and β2-MG in phase II were significantly higher than those in phase I, the differences were statistically significant (all P<0.001), respectively. The serum levels of miR-1246 (2.61±1.13), miR-4449 (3.18±1.64 ) and β2-MG (8.04±3.27 mg/L) in the recurrence group(1.55±0.62, 1.92±0.95, 4.96±1.85mg/L) were significantly higher than those in the initial diagnosis group, the differences were statistically significant (t=10.217,12.116,8.530，all P<0.001). ROC curve analysis showed that the area under the curve (0.950, 95%CI：0.887~0.995) of miR-1246，miR-4449 and β2-MG combined diagnosis MM was the largest, and its sensitivity and specificity were 98.2% and 85.0%, respectively. Conclusion　The levels of serum miR-1246 and miR-4449 in MM patients were significantly increased, and showed an upward trend with the progression of MM stage. The detection of miR-1246 and miR-4449 combined with β2- MG can improve the sensitivity of MM diagnosis.

参考文献/References:

[1] 张蓉, 李国辉, 刘小五, 等．初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J]．现代检验医学杂志, 2020, 35(1):101-104． ZHANG Rong, LI Guohui, LIU Xiaowu, et al. Value of peripheral blood lymphocyte absolute value/monocyte absolute value ratio in predicting clinical prognosis of newly diagnosed multiple myeloma patients[J]. Journal of Modern Laboratory Medicine, 2020, 35(1): 101-104.
[2] ADAMIA S, ABIATARI I, AMIN S B , et al. The effects of microRNA deregulation on pre-RNA processing network in multiple myeloma[J]. Leukemia, 2020, 34(1):167-179.
[3] POURHANIFEH M H, MAHJOUBIN-TEHRAN M, SHAFIEE A, et al. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis[J]. IUBMB Life, 2020 , 72(3):314-333.
[4] SUYAL S, SINGH M P, SHEKHAR H, et al. In silico screening of proteins targeting circulating miRNAs for improved diagnosis of multiple myeloma[J]. Biochemical and Biophysical Research Communications, 2018, 497(2): 577-582.
[5] XU Peipei, XIA Tian, LING Yipeng, et al. MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(33): e16711.
[6] SHAIKH S P, IRFAN S M, SHEIKH S S. Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma[J]. Pakistan Journal of Medical Sciences, 2019, 35(1): 90-94.
[7] 中国医师协会血液科医师分会, 中华医学会血液学 分会, 中国医师协会多发性骨髓瘤专业委员会. 中 国多发性骨髓瘤诊治指南(2017 年修订)[J]. 中华内 科杂志,2017,56 (11): 866-870. Chinese Hematology Association, Chinese Society of Hematology, Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China ( 2017 revision )[J]. Chinese Journal of Internal Medicine, 2017, 56 (11): 866-870.
[8] YAMAMOTO T, KOSAKA N, HATTORI Y, et al. A challenge to aging society by microRNA in extracellular vesicles: microRNA in extracellular vesicles as promising biomarkers and novel therapeutic targets in multiple myeloma [J]. Journal of Clinical Medicine, 2018, 7(3): 55.
[9] MISIEWICZ-KRZEMINSKA I, KRZEMINSKI P, CORCHETE L A, et al. Factors regulating microRNA expression and function in multiple myeloma. noncoding RNA [J]. Noncoding RNA, 2019, 5(1): 9.
[10] LONG Shifeng, LONG Shengping, HE Honglei, et al.MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6 [J]. Exp Ther Med, 2019 , 17(6):4741-4747.
[11] FEDERICO C, SACCO A, BELOTTI A, et al. Circulating microRNAs and their role in multiple myeloma [J]. Noncoding RNA, 2019, 5(2): 37.
[12] MANIER S, LIU C J, AVET-LOISEAU H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma[J]. Blood. 2017, 129(17):2429-2436.
[13] 吴晓颖, 施菊妹, 陶怡, 等. IGF- Ⅰ , β2-MG 和SF 在 多发性骨髓瘤患者中的诊断价值及其与临床分期的关 系[J]. 中国实验血液学杂志, 2018, 26(3): 802-806. WU Xiaoying, SHI Jumei, TAO Yi, et al. Diagnostic value of IGF-I,β2-MG and SF for patients with multiple myeloma and their relationship with clinical staging [J]. Journal of Experimental Hematology, 2018, 26 (3): 802-806.
[14] LIU Ni , YANG Jingyu, YUAN Ruili , et al. Effects of miR-181a on the biological function of multiple myeloma[J].Oncol Rep, 2019, 42(1):291-300.
[15] 张煜, 陈宏梅, 卢旭, 等．多发性骨髓瘤患者血清外 泌体miR-223-3p 的表达及临床意义[J]. 中华检验医 学杂志, 2020, 43(4):446-451. ZHANG Yu, CHEN Homgmei, LU Xu, et al. Expression and clinical value of serum exosomal miR- 223-3p in multiple myeloma patients [J]. Chinese Journal of Laboratory Medicine, 2020, 43 (4): 446-451.
[16] REN Yuyue, LI Xiaoyun, WANG Wei, et al. Expression of peripheral blood miRNA-720 and miRNA-1246 can be used as a predictor for outcome in multiple myeloma patients[J]. Clin Lymphoma Myeloma Leuk, 2017, 17(7):415-423.
[17] SHEN Xianjuan, YE Yan, QI Jing, et al. Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma[J].Clin Chem Lab Med, 2017, 55(5):748-754.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(02):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(02):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(02):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(02):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]

备注/Memo

备注/Memo:
基金项目：保定市科学计划与发展指导计划项目（18ZF602）。
作者简介：于艳（1989-）, 女，本科，主管技师，主要从事临床血液病检验诊断研究，E-mail：y1101761393@163.com。
更新日期/Last Update: 1900-01-01